Mangoceuticals, Inc.

NasdaqCM MGRX

Mangoceuticals, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD -8.86 M

Mangoceuticals, Inc. EBIT is USD -8.86 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -21.16% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Mangoceuticals, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -7.31 M, a -316.72% change year over year.
Mangoceuticals, Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -1.76 M.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqCM: MGRX

Mangoceuticals, Inc.

CEO	Mr. Jacob D. Cohen
IPO Date	March 21, 2023
Location	United States
Headquarters	15110 North Dallas Parkway
Employees	3
Sector	Health Care
Industries Telehealth Pharmaceuticals

Description

Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

Key trends

Past 5 years